[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2015001127A1 - Nuevas variantes del receptor iib de fc gamma - Google Patents

Nuevas variantes del receptor iib de fc gamma

Info

Publication number
CL2015001127A1
CL2015001127A1 CL2015001127A CL2015001127A CL2015001127A1 CL 2015001127 A1 CL2015001127 A1 CL 2015001127A1 CL 2015001127 A CL2015001127 A CL 2015001127A CL 2015001127 A CL2015001127 A CL 2015001127A CL 2015001127 A1 CL2015001127 A1 CL 2015001127A1
Authority
CL
Chile
Prior art keywords
receiver
new variants
gamma iib
iib
gamma
Prior art date
Application number
CL2015001127A
Other languages
English (en)
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Reno Winter
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of CL2015001127A1 publication Critical patent/CL2015001127A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)

Abstract

SECUENCIA DE ÁCIDOS NUCLEICOS DE RECEPTORES DE FC SOLUBLES; VECTOR Y PROTEÍNA QUE LA COMPRENDEN; COMPOSICIÓN FARMACÉUTICA; CÉLULA HOSPEDERA; METODO DE FABRICACIÓN DE DICHA COMPOSICIÓN.
CL2015001127A 2012-10-30 2015-04-29 Nuevas variantes del receptor iib de fc gamma CL2015001127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Publications (1)

Publication Number Publication Date
CL2015001127A1 true CL2015001127A1 (es) 2015-12-18

Family

ID=49679480

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001127A CL2015001127A1 (es) 2012-10-30 2015-04-29 Nuevas variantes del receptor iib de fc gamma

Country Status (28)

Country Link
US (1) US10028998B2 (es)
EP (1) EP2914624B1 (es)
JP (2) JP6423351B2 (es)
KR (1) KR102170674B1 (es)
CN (1) CN104918955B (es)
AU (1) AU2013340831B2 (es)
BR (1) BR112015008815A2 (es)
CA (1) CA2887164C (es)
CL (1) CL2015001127A1 (es)
DK (1) DK2914624T3 (es)
EA (1) EA033437B9 (es)
ES (1) ES2628049T3 (es)
HK (1) HK1209765A1 (es)
HR (1) HRP20170894T1 (es)
HU (1) HUE032786T2 (es)
IL (1) IL238528A (es)
IN (1) IN2015DN03206A (es)
LT (1) LT2914624T (es)
MX (1) MX359802B (es)
MY (1) MY173686A (es)
NZ (1) NZ706884A (es)
PH (1) PH12015500771B1 (es)
PL (1) PL2914624T3 (es)
PT (1) PT2914624T (es)
RS (1) RS56075B1 (es)
SG (1) SG11201502749VA (es)
SI (1) SI2914624T1 (es)
WO (1) WO2014068012A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
EA034176B1 (ru) 2013-10-16 2020-01-14 Зуппремоль Гмбх РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えＦｃγＲＩＩｂ
MX2020014212A (es) * 2018-06-25 2021-03-09 Basf Coatings Gmbh Metodo para producir un revestimiento optimizado y un revestimiento que se puede obtener mediante el uso de dicho metodo.
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
US12030945B2 (en) 2022-10-25 2024-07-09 Seismic Therapeutic, Inc. Variant IgG Fc polypeptides and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
WO1997000957A1 (en) 1995-06-23 1997-01-09 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE519784T1 (de) 2003-11-26 2011-08-15 Max Planck Gesellschaft An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
ATE499384T1 (de) 2005-12-13 2011-03-15 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

Also Published As

Publication number Publication date
CA2887164A1 (en) 2014-05-08
RS56075B1 (sr) 2017-10-31
WO2014068012A1 (en) 2014-05-08
ES2628049T3 (es) 2017-08-01
IL238528A0 (en) 2015-06-30
SG11201502749VA (en) 2015-05-28
PH12015500771A1 (en) 2015-06-08
US20140120080A1 (en) 2014-05-01
US10028998B2 (en) 2018-07-24
JP6423351B2 (ja) 2018-11-14
AU2013340831B2 (en) 2017-11-23
HK1209765A1 (en) 2016-04-08
EA033437B9 (ru) 2020-03-19
JP2016503289A (ja) 2016-02-04
EP2914624B1 (en) 2017-03-15
NZ706884A (en) 2019-05-31
HRP20170894T1 (hr) 2017-09-08
BR112015008815A2 (pt) 2017-11-21
PT2914624T (pt) 2017-06-07
MY173686A (en) 2020-02-15
EA201590845A1 (ru) 2015-08-31
PL2914624T3 (pl) 2017-09-29
CA2887164C (en) 2020-12-29
KR20150122621A (ko) 2015-11-02
IN2015DN03206A (es) 2015-10-02
JP2018186833A (ja) 2018-11-29
HUE032786T2 (en) 2017-10-30
EA033437B1 (ru) 2019-10-31
LT2914624T (lt) 2017-06-26
DK2914624T3 (en) 2017-06-26
EP2914624A1 (en) 2015-09-09
PH12015500771B1 (en) 2015-06-08
MX2015005266A (es) 2015-10-26
SI2914624T1 (sl) 2017-07-31
IL238528A (en) 2017-07-31
AU2013340831A1 (en) 2015-04-30
MX359802B (es) 2018-10-10
KR102170674B1 (ko) 2020-10-28
CN104918955A (zh) 2015-09-16
CN104918955B (zh) 2018-10-09

Similar Documents

Publication Publication Date Title
CL2015001127A1 (es) Nuevas variantes del receptor iib de fc gamma
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2022000026A (es) Anticuerpos para tau.
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201691991A1 (ru) Мультиспецифические антитела
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2016016886A (es) Anticuerpos anti-axl.
MX2016000997A (es) Metodos y composiciones para detectar contaminacion bacteriana.
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2019012708A (es) Anticuerpos teicoicos anti-pared y conjugados.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2015016354A (es) Anticuerpos anti-acido teicoico de pared y conjugados.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
BR112018006991A2 (pt) receptores de antígeno quiméricos direcionados ao psca
EP3096784A4 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts